JP2012530715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530715A5 JP2012530715A5 JP2012516315A JP2012516315A JP2012530715A5 JP 2012530715 A5 JP2012530715 A5 JP 2012530715A5 JP 2012516315 A JP2012516315 A JP 2012516315A JP 2012516315 A JP2012516315 A JP 2012516315A JP 2012530715 A5 JP2012530715 A5 JP 2012530715A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administration
- subject
- nucleobase sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21803109P | 2009-06-17 | 2009-06-17 | |
| US61/218,031 | 2009-06-17 | ||
| PCT/US2010/039077 WO2010148249A1 (en) | 2009-06-17 | 2010-06-17 | Compositions and methods for modulation of smn2 splicing in a subject |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015040152A Division JP6064139B2 (ja) | 2009-06-17 | 2015-03-02 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012530715A JP2012530715A (ja) | 2012-12-06 |
| JP2012530715A5 true JP2012530715A5 (enExample) | 2013-08-01 |
| JP5707396B2 JP5707396B2 (ja) | 2015-04-30 |
Family
ID=43356760
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516315A Active JP5707396B2 (ja) | 2009-06-17 | 2010-06-17 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2015040152A Active JP6064139B2 (ja) | 2009-06-17 | 2015-03-02 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2016216200A Active JP6370860B2 (ja) | 2009-06-17 | 2016-11-04 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2018128926A Active JP6637121B2 (ja) | 2009-06-17 | 2018-07-06 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2019227997A Pending JP2020073498A (ja) | 2009-06-17 | 2019-12-18 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2021180965A Pending JP2022025131A (ja) | 2009-06-17 | 2021-11-05 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2023185174A Pending JP2024012416A (ja) | 2009-06-17 | 2023-10-30 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2025161821A Pending JP2026004402A (ja) | 2009-06-17 | 2025-09-29 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015040152A Active JP6064139B2 (ja) | 2009-06-17 | 2015-03-02 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2016216200A Active JP6370860B2 (ja) | 2009-06-17 | 2016-11-04 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2018128926A Active JP6637121B2 (ja) | 2009-06-17 | 2018-07-06 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2019227997A Pending JP2020073498A (ja) | 2009-06-17 | 2019-12-18 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2021180965A Pending JP2022025131A (ja) | 2009-06-17 | 2021-11-05 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2023185174A Pending JP2024012416A (ja) | 2009-06-17 | 2023-10-30 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
| JP2025161821A Pending JP2026004402A (ja) | 2009-06-17 | 2025-09-29 | 被験体におけるｓｍｎ２スプライシングのモジュレーションのための組成物および方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US8980853B2 (enExample) |
| EP (4) | EP3449926B1 (enExample) |
| JP (8) | JP5707396B2 (enExample) |
| KR (9) | KR20240036132A (enExample) |
| CN (5) | CN115227709A (enExample) |
| AU (2) | AU2010262862C1 (enExample) |
| CA (1) | CA2765396C (enExample) |
| CY (2) | CY1120807T1 (enExample) |
| DK (2) | DK3449926T3 (enExample) |
| ES (2) | ES2699827T3 (enExample) |
| HK (1) | HK1246648B (enExample) |
| HR (2) | HRP20181712T1 (enExample) |
| HU (2) | HUE046966T2 (enExample) |
| IL (2) | IL217014A (enExample) |
| LT (2) | LT3449926T (enExample) |
| MX (3) | MX361732B (enExample) |
| NO (1) | NO2020008I1 (enExample) |
| NZ (2) | NZ624712A (enExample) |
| PL (2) | PL3305302T3 (enExample) |
| PT (2) | PT3449926T (enExample) |
| RU (2) | RU2566724C9 (enExample) |
| SI (2) | SI3305302T1 (enExample) |
| SM (2) | SMT202000020T1 (enExample) |
| TR (1) | TR201816256T4 (enExample) |
| WO (1) | WO2010148249A1 (enExample) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006213686A1 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| ES2397113T3 (es) * | 2005-06-23 | 2013-03-04 | Isis Pharmaceuticals, Inc. | Composiciones y procedimientos para modular el corte y empalme de SMN2 |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| SG171914A1 (en) | 2008-12-02 | 2011-07-28 | Chiralgen Ltd | Method for the synthesis of phosphorus atom modified nucleic acids |
| CN115227709A (zh) | 2009-06-17 | 2022-10-25 | 冷泉港实验室 | 用于在对象中调节smn2剪接的组合物和方法 |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF |
| US8802642B2 (en) | 2010-04-28 | 2014-08-12 | Iowa State University Research Foundation, Inc. | Spinal muscular atrophy treatment via targeting SMN2 catalytic core |
| KR102182663B1 (ko) | 2010-05-28 | 2020-11-25 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| AU2011325956B2 (en) | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| IL273838B (en) | 2011-05-05 | 2022-09-01 | Sarepta Therapeutics Inc | Peptide and oligonucleotide conjugates, preparations containing them and their uses |
| CA2836364C (en) | 2011-05-25 | 2021-01-26 | Universite Paris Descartes | Erk inhibitors for use in treating spinal muscular atrophy |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| JP2014533944A (ja) | 2011-11-11 | 2014-12-18 | サンタリス ファーマ アー／エスＳａｎｔａｒｉｓ Ｐｈａｒｍａ Ａ／Ｓ | Ｓｍｎ２スプライシングの調節のための化合物 |
| JP2015500204A (ja) | 2011-11-18 | 2015-01-05 | サレプタ セラピューティクス， インコーポレイテッド | 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット |
| AU2012345638C1 (en) | 2011-11-30 | 2018-10-18 | Sarepta Therapeutics, Inc. | Induced exon inclusion in spinal muscle atrophy |
| EP2788087A4 (en) * | 2011-12-06 | 2015-08-26 | Ohio State Innovation Foundation | Non-ionic, low-osmolar contrast agents for the administration of antisense oligonucleotides and the treatment of diseases |
| WO2013148283A1 (en) | 2012-03-30 | 2013-10-03 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| CN112007045B (zh) | 2012-07-13 | 2026-01-06 | 波涛生命科学有限公司 | 手性控制 |
| DK2872485T3 (da) | 2012-07-13 | 2021-03-08 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| WO2014110291A1 (en) * | 2013-01-09 | 2014-07-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
| WO2014113540A1 (en) * | 2013-01-16 | 2014-07-24 | Iowa State University Research Foundation, Inc. | A deep intronic target for splicing correction on spinal muscular atrophy gene |
| CN111254145A (zh) | 2013-03-14 | 2020-06-09 | Ionis制药公司 | 用于调节tau表达的组合物和方法 |
| WO2014169243A2 (en) * | 2013-04-12 | 2014-10-16 | The Curators Of The University Of Missouri | Smn2 element 1 antisense compositions and methods and uses thereof |
| TWI657819B (zh) | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| KR20160042917A (ko) | 2013-07-25 | 2016-04-20 | 엑시큐어, 인크. | 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물 |
| WO2015023797A1 (en) | 2013-08-13 | 2015-02-19 | Northwestern University | Lipophilic nanoparticles for drug delivery |
| EP3033422A4 (en) | 2013-08-16 | 2017-08-02 | Rana Therapeutics Inc. | Oligonucleotides targeting euchromatin regions of genes |
| ES2779302T3 (es) | 2013-09-04 | 2020-08-14 | Cold Spring Harbor Laboratory | Reducción de la degradación de ARNm con mediación sin sentido |
| KR102275504B1 (ko) | 2013-09-05 | 2021-07-09 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함 |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| KR102423317B1 (ko) | 2014-01-16 | 2022-07-22 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
| MA39835A (fr) | 2014-04-17 | 2017-02-22 | Biogen Ma Inc | Compositions et procédés de modulation de l'épissage du smn2 chez un patient |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| CN104163871A (zh) * | 2014-08-12 | 2014-11-26 | 大连医科大学 | 抗肿瘤的特异性剪接因子及制备方法 |
| WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
| EP3201339A4 (en) | 2014-10-03 | 2018-09-19 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| US10858650B2 (en) | 2014-10-30 | 2020-12-08 | The General Hospital Corporation | Methods for modulating ATRX-dependent gene repression |
| US10517924B2 (en) | 2014-11-24 | 2019-12-31 | Northwestern University | High density lipoprotein nanoparticles for inflammation |
| WO2016149455A2 (en) | 2015-03-17 | 2016-09-22 | The General Hospital Corporation | The rna interactome of polycomb repressive complex 1 (prc1) |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| US10851371B2 (en) | 2015-04-10 | 2020-12-01 | Ionis Pharmaceuticals, Inc. | Modulation of SMN expression |
| US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| AU2016317667A1 (en) * | 2015-08-28 | 2018-03-22 | Sarepta Therapeutics, Inc. | Modified antisense oligomers for exon inclusion in spinal muscular atrophy |
| WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| AU2016334804B2 (en) | 2015-10-09 | 2022-03-31 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| WO2017087486A1 (en) | 2015-11-16 | 2017-05-26 | Ohio State Innovation Foundation | Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| EP3389672A4 (en) | 2015-12-14 | 2019-08-14 | Cold Spring Harbor Laboratory | COMPOSITIONS AND METHOD FOR THE TREATMENT OF LIVER DISEASES |
| CA3005254A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13 |
| ES2882500T3 (es) | 2015-12-14 | 2021-12-02 | Cold Spring Harbor Laboratory | Oligómeros antisentido para el tratamiento del síndrome de Dravet |
| JP2018538288A (ja) | 2015-12-14 | 2018-12-27 | コールド スプリング ハーバー ラボラトリー | アラジール症候群の処置のためのアンチセンスオリゴマー |
| EP4104867A3 (en) | 2015-12-14 | 2023-03-01 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of central nervous system diseases |
| MY200252A (en) | 2016-04-18 | 2023-12-16 | Sarepta Therapeutics Inc | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| JP7186094B2 (ja) | 2016-05-06 | 2022-12-08 | イグジキュア オペレーティング カンパニー | インターロイキン１７受容体ｍＲＮＡの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド（ＡＳＯ）を提示するリポソーム系球状核酸（ＳＮＡ）構築物 |
| JP7075359B2 (ja) | 2016-06-14 | 2022-05-25 | バイオジェン・エムエイ・インコーポレイテッド | オリゴヌクレオチドの精製のための疎水性相互作用クロマトグラフィー |
| WO2017218884A1 (en) | 2016-06-16 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Combinations for the modulation of smn expression |
| WO2017223258A1 (en) | 2016-06-24 | 2017-12-28 | Biogen Ma Inc. | Synthesis of thiolated oligonucleotides without a capping step |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| ES2963428T3 (es) | 2016-09-29 | 2024-03-27 | Biogen Ma Inc | Compuestos y métodos para reducir la expresión de Tau |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| MX2019010275A (es) | 2017-02-28 | 2019-10-15 | Univ Pennsylvania | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este. |
| CN110536964A (zh) * | 2017-03-10 | 2019-12-03 | 国立研究开发法人国立成育医疗研究中心 | 反义寡核苷酸和糖原贮积病Ia型预防或治疗用组合物 |
| CN110536694A (zh) | 2017-04-20 | 2019-12-03 | Atyr 医药公司 | 用于治疗肺部炎症的组合物和方法 |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| KR102547579B1 (ko) | 2017-06-19 | 2023-06-26 | 스미토모 긴조쿠 고잔 가부시키가이샤 | 근적외선 경화형 잉크 조성물과 그의 제조 방법, 근적외선 경화막 및 광조형법 |
| BR112020000410A2 (pt) | 2017-07-10 | 2020-07-14 | Geron Corporation | processo aprimorado para preparar imetelstat |
| KR102636383B1 (ko) | 2017-08-04 | 2024-02-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| SI3673080T1 (sl) | 2017-08-25 | 2024-03-29 | Stoke Therapeutics, Inc. | Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni |
| US11596646B2 (en) | 2017-10-12 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2019079637A2 (en) | 2017-10-18 | 2019-04-25 | Sarepta Therapeutics, Inc. | ANTISENSE OLIGOMERIC COMPOUNDS |
| EP3700570B1 (en) | 2017-10-23 | 2025-01-08 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases |
| CN120505370A (zh) | 2017-11-08 | 2025-08-19 | 诺华股份有限公司 | 制备病毒载体的手段和方法及其用途 |
| CN120310791A (zh) | 2018-01-12 | 2025-07-15 | 百时美施贵宝公司 | 靶向α-突触核蛋白的反义寡核苷酸及其用途 |
| US11667941B2 (en) * | 2018-01-12 | 2023-06-06 | Camena Bioscience Limited | Compositions and methods for template-free geometric enzymatic nucleic acid synthesis |
| US12241065B2 (en) | 2018-01-12 | 2025-03-04 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| WO2019147960A1 (en) | 2018-01-25 | 2019-08-01 | Biogen Ma Inc. | Methods of treating spinal muscular atrophy |
| US20210002640A1 (en) * | 2018-02-28 | 2021-01-07 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors |
| WO2019168558A1 (en) * | 2018-02-28 | 2019-09-06 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors |
| EP3763815A4 (en) | 2018-03-09 | 2021-12-15 | Daiichi Sankyo Company, Limited | THERAPEUTIC FOR GLYCOGEN STORAGE DISEASE OF TYPE IA |
| JP7333079B2 (ja) | 2018-03-19 | 2023-08-24 | 国立大学法人 東京医科歯科大学 | 毒性が軽減した核酸 |
| WO2019213525A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| US12228571B2 (en) | 2018-06-08 | 2025-02-18 | Novartis Ag | Cell-based assay for measuring drug product potency |
| CA3105174A1 (en) | 2018-06-27 | 2020-01-02 | Reborna Biosciences, Inc. | Prophylactic or therapeutic agent for spinal muscular atrophy |
| WO2020037161A1 (en) * | 2018-08-15 | 2020-02-20 | Biogen Ma Inc. | Combination therapy for spinal muscular atrophy |
| JP2022509372A (ja) | 2018-10-29 | 2022-01-20 | バイオジェン・エムエイ・インコーポレイテッド | 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント |
| AU2019389047A1 (en) | 2018-11-30 | 2021-05-20 | Novartis Ag | AAV viral vectors and uses thereof |
| KR20210102294A (ko) | 2018-12-06 | 2021-08-19 | 바이오젠 엠에이 인코포레이티드 | 근위축성 측삭 경화증에서 치료요법적 중재를 안내하기 위한 신경필라멘트 단백질 |
| US12590324B2 (en) | 2019-01-14 | 2026-03-31 | Camena Bioscience Limited | Compositions and methods for template-free geometric enzymatic nucleic acid synthesis |
| US20220098578A1 (en) | 2019-01-31 | 2022-03-31 | Bar Ilan University | Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy |
| CN119320388A (zh) | 2019-02-04 | 2025-01-17 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| KR102913697B1 (ko) | 2019-02-05 | 2026-01-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| WO2020191212A1 (en) | 2019-03-20 | 2020-09-24 | President And Fellows Of Harvard College | Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases |
| US12458657B2 (en) | 2019-04-18 | 2025-11-04 | Brown University | Neurogenesis |
| MA55891A (fr) | 2019-05-08 | 2022-03-16 | Ajinomoto Kk | Synthèses en phase liquide convergente d'oligonucléotides |
| HUE064071T2 (hu) | 2019-07-19 | 2024-02-28 | Biogen Ma Inc | Eljárások a spinális izomatrófia kezelésére vagy megelõzésére |
| WO2021030766A1 (en) * | 2019-08-15 | 2021-02-18 | Biogen Ma Inc. | Combination therapy for spinal muscular atrophy |
| WO2021089736A1 (en) * | 2019-11-06 | 2021-05-14 | Association Institut De Myologie | Combined therapy for muscular diseases |
| RU2738093C9 (ru) * | 2019-12-23 | 2020-12-29 | Общество с ограниченной ответственностью "Гелеспон" | Способ синтеза 2'-о-(2-метоксиэтил) тиофосфатного олигонуклеотида |
| PH12022552258A1 (en) | 2020-02-28 | 2023-11-20 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating smn2 |
| CN113444722B (zh) * | 2020-03-24 | 2024-09-24 | 中国科学院脑科学与智能技术卓越创新中心 | 单碱基编辑介导的剪接修复在制备治疗脊髓性肌萎缩症中的应用 |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| MX2023001349A (es) * | 2020-07-31 | 2023-02-27 | Ractigen Therapeutics | Tratamiento de combinacion de sma con moduladores de arnsa y arnm. |
| AR125239A1 (es) | 2021-04-02 | 2023-06-28 | Kumiai Chemical Industry Co | Compuesto heterocíclico y uso del mismo |
| US20250235554A1 (en) | 2021-10-25 | 2025-07-24 | Novartis Ag | Methods for improving adeno-associated virus (aav) delivery |
| CA3241399A1 (en) | 2021-12-20 | 2023-06-29 | Marco PREUSSNER | Methods and agents for increasing rbm3 expression |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| US20240150759A1 (en) * | 2022-11-04 | 2024-05-09 | The Board Of Trustees Of The Leland Stanford Junior University | Splicing Modulators for the Treatment of Timothy Syndrome |
| WO2025035143A1 (en) | 2023-08-10 | 2025-02-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of spinal muscular atrophy |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
| FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
| US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
| US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
| US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
| JPS638396A (ja) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
| US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
| US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
| US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
| US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| FR2645345A1 (fr) | 1989-03-31 | 1990-10-05 | Thomson Csf | Procede de modulation dirigee de la composition ou du dopage de semi-conducteurs, notamment pour la realisation de composants electroniques monolithiques de type planar, utilisation et produits correspondants |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
| US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| DK0942000T3 (da) | 1989-10-24 | 2004-11-01 | Isis Pharmaceuticals Inc | 2'-modificerede oligonukleotider |
| US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
| US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
| US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
| AU7579991A (en) | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| ATE167523T1 (de) | 1990-05-11 | 1998-07-15 | Microprobe Corp | Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden |
| US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
| EP0556301B1 (en) | 1990-11-08 | 2001-01-10 | Hybridon, Inc. | Incorporation of multiple reporter groups on synthetic oligonucleotides |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
| ES2103918T3 (es) | 1991-10-17 | 1997-10-01 | Ciba Geigy Ag | Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios. |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
| US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| WO1994022864A1 (en) | 1993-03-30 | 1994-10-13 | Sterling Winthrop Inc. | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
| DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
| EP1897942A1 (en) | 1993-05-11 | 2008-03-12 | The University Of North Carolina At Chapel Hill | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| PL184202B1 (pl) | 1994-02-28 | 2002-09-30 | Agritech Technologies Ltd | Nieterapeutyczny sposób zwiększania zdolności produkcyjnej ptaka, fuzyjne białko heterologiczne obejmujące białko ptasiej inhibiny oraz sposób wytwarzania fuzyjnego białka heterologicznego, gen fuzyjny, komórka gospodarza i wektor |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| EP0708178A1 (en) * | 1994-10-19 | 1996-04-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| US7034009B2 (en) | 1995-10-26 | 2006-04-25 | Sirna Therapeutics, Inc. | Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| DE69637256T2 (de) | 1996-01-16 | 2008-06-19 | Sirna Therapeutics, Inc., Boulder | Synthese von Methoxynukleoside und enzymatische Nukleisäure Moleküle |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US6172216B1 (en) | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| US6649411B2 (en) | 1999-07-30 | 2003-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides |
| US6770633B1 (en) | 1999-10-26 | 2004-08-03 | Immusol, Inc. | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US6962906B2 (en) | 2000-03-14 | 2005-11-08 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
| WO2001085751A1 (en) | 2000-05-09 | 2001-11-15 | Reliable Biopharmaceutical, Inc. | Polymeric compounds useful as prodrugs |
| WO2002038738A2 (en) | 2000-11-09 | 2002-05-16 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
| US6376508B1 (en) | 2000-12-13 | 2002-04-23 | Academia Sinica | Treatments for spinal muscular atrophy |
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| GB0219143D0 (en) | 2002-08-16 | 2002-09-25 | Univ Leicester | Modified tailed oligonucleotides |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン， インコーポレイテッド | 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ |
| JP2004344072A (ja) * | 2003-05-22 | 2004-12-09 | Japan Science & Technology Agency | Ｓｍｎ遺伝子のスプライシング調節エレメント |
| WO2004113867A2 (en) | 2003-06-16 | 2004-12-29 | University Of Massachusetts | Exon analysis |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| GB0425625D0 (en) * | 2004-11-22 | 2004-12-22 | Royal College Of Surgeons Ie | Treatment of disease |
| US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
| US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
| ES2397113T3 (es) * | 2005-06-23 | 2013-03-04 | Isis Pharmaceuticals, Inc. | Composiciones y procedimientos para modular el corte y empalme de SMN2 |
| JP4223027B2 (ja) | 2005-06-30 | 2009-02-12 | シャープ株式会社 | 画像形成装置及び秘匿データ送信方法 |
| WO2007047913A2 (en) | 2005-10-20 | 2007-04-26 | Isis Pharmaceuticals, Inc | Compositions and methods for modulation of lmna expression |
| US20070105807A1 (en) | 2005-11-10 | 2007-05-10 | Sazani Peter L | Splice switch oligomers for TNF superfamily receptors and their use in treatment of disease |
| SI2161038T1 (sl) * | 2006-01-26 | 2014-05-30 | Isis Pharmaceuticals, Inc. | Sestavki in njihove uporabe, usmerjeni proti huntingtinu |
| US8129515B2 (en) | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
| ES2351674T3 (es) | 2006-01-27 | 2011-02-09 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6. |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| WO2008101157A1 (en) | 2007-02-15 | 2008-08-21 | Isis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| EP2176280B2 (en) | 2007-07-05 | 2015-06-24 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009120700A2 (en) | 2008-03-26 | 2009-10-01 | Families Of Spinal Muscular Atrophy | Inhibition of dcps |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| WO2010123594A2 (en) | 2009-01-15 | 2010-10-28 | Children's Medical Center Corporation | Device for filtration of fluids there through and accompanying method |
| US20120021515A1 (en) | 2009-02-06 | 2012-01-26 | Swayze Eric E | Oligomeric compounds and methods |
| US20120149757A1 (en) | 2009-04-13 | 2012-06-14 | Krainer Adrian R | Compositions and methods for modulation of smn2 splicing |
| CN115227709A (zh) | 2009-06-17 | 2022-10-25 | 冷泉港实验室 | 用于在对象中调节smn2剪接的组合物和方法 |
| WO2011032109A1 (en) | 2009-09-11 | 2011-03-17 | Sma Foundation | Biomarkers for spinal muscular atrophy |
| US8183002B2 (en) | 2009-12-03 | 2012-05-22 | Abbott Laboratories | Autoantibody enhanced immunoassays and kits |
| US10653713B2 (en) | 2010-10-06 | 2020-05-19 | Medtronic, Inc. | Methods for distributing agents to areas of brain |
| EP2732289B1 (en) | 2011-07-13 | 2018-04-11 | Acumen Pharmaceuticals, Inc. | ANTIBODIES, KIT AND in vitro METHOD FOR DETECTING AMYLOID BETA OLIGOMERS |
| WO2014110291A1 (en) | 2013-01-09 | 2014-07-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
| US20140367278A1 (en) | 2013-06-12 | 2014-12-18 | PharmOptima, LLC | Methods for Detecting Survival Motor Neuron (SMN) Protein in Whole Blood or Cerebral Spinal Fluid |
-
2010
- 2010-06-17 CN CN202210540428.XA patent/CN115227709A/zh active Pending
- 2010-06-17 MX MX2015008433A patent/MX361732B/es unknown
- 2010-06-17 ES ES17203913T patent/ES2699827T3/es active Active
- 2010-06-17 NZ NZ624712A patent/NZ624712A/en unknown
- 2010-06-17 KR KR1020247007557A patent/KR20240036132A/ko not_active Ceased
- 2010-06-17 EP EP18185820.0A patent/EP3449926B1/en active Active
- 2010-06-17 US US13/380,021 patent/US8980853B2/en active Active
- 2010-06-17 KR KR1020177011876A patent/KR20170054537A/ko not_active Withdrawn
- 2010-06-17 ES ES18185820T patent/ES2761614T3/es active Active
- 2010-06-17 KR KR1020227019810A patent/KR20220084437A/ko not_active Ceased
- 2010-06-17 PT PT181858200T patent/PT3449926T/pt unknown
- 2010-06-17 KR KR1020127001244A patent/KR20120093138A/ko not_active Ceased
- 2010-06-17 CN CN2010800368070A patent/CN102665731A/zh active Pending
- 2010-06-17 HU HUE18185820A patent/HUE046966T2/hu unknown
- 2010-06-17 DK DK18185820T patent/DK3449926T3/da active
- 2010-06-17 KR KR1020267002500A patent/KR20260021813A/ko active Pending
- 2010-06-17 LT LTEP18185820.0T patent/LT3449926T/lt unknown
- 2010-06-17 PT PT17203913T patent/PT3305302T/pt unknown
- 2010-06-17 AU AU2010262862A patent/AU2010262862C1/en active Active
- 2010-06-17 LT LTEP17203913.3T patent/LT3305302T/lt unknown
- 2010-06-17 RU RU2012101491A patent/RU2566724C9/ru active
- 2010-06-17 KR KR1020207012412A patent/KR20200047790A/ko not_active Ceased
- 2010-06-17 CN CN202210541466.7A patent/CN115227710A/zh active Pending
- 2010-06-17 CA CA2765396A patent/CA2765396C/en active Active
- 2010-06-17 EP EP19201392.8A patent/EP3643783A1/en active Pending
- 2010-06-17 CN CN202310217516.0A patent/CN116440150A/zh active Pending
- 2010-06-17 NZ NZ597071A patent/NZ597071A/en unknown
- 2010-06-17 DK DK17203913.3T patent/DK3305302T3/en active
- 2010-06-17 TR TR2018/16256T patent/TR201816256T4/tr unknown
- 2010-06-17 RU RU2015139553A patent/RU2683772C2/ru active
- 2010-06-17 KR KR1020197003809A patent/KR101965868B1/ko active Active
- 2010-06-17 JP JP2012516315A patent/JP5707396B2/ja active Active
- 2010-06-17 SM SM20200020T patent/SMT202000020T1/it unknown
- 2010-06-17 EP EP17203913.3A patent/EP3305302B1/en active Active
- 2010-06-17 HU HUE17203913A patent/HUE039741T2/hu unknown
- 2010-06-17 SI SI201031784T patent/SI3305302T1/sl unknown
- 2010-06-17 SI SI201031946T patent/SI3449926T1/sl unknown
- 2010-06-17 KR KR1020217014192A patent/KR20210057223A/ko not_active Ceased
- 2010-06-17 PL PL17203913T patent/PL3305302T3/pl unknown
- 2010-06-17 CN CN201710003678.9A patent/CN106983768B/zh active Active
- 2010-06-17 WO PCT/US2010/039077 patent/WO2010148249A1/en not_active Ceased
- 2010-06-17 PL PL18185820T patent/PL3449926T3/pl unknown
- 2010-06-17 KR KR1020197009268A patent/KR20190037378A/ko not_active Ceased
- 2010-06-17 SM SM20180587T patent/SMT201800587T1/it unknown
- 2010-06-17 EP EP10790221.5A patent/EP2442816A4/en not_active Withdrawn
- 2010-06-17 MX MX2011014004A patent/MX2011014004A/es active IP Right Grant
-
2011
- 2011-12-15 IL IL217014A patent/IL217014A/en active Protection Beyond IP Right Term
- 2011-12-16 MX MX2018015635A patent/MX2018015635A/es unknown
-
2015
- 2015-02-09 US US14/617,388 patent/US9717750B2/en active Active
- 2015-03-02 JP JP2015040152A patent/JP6064139B2/ja active Active
-
2016
- 2016-01-21 AU AU2016200344A patent/AU2016200344B2/en active Active
- 2016-04-13 IL IL245096A patent/IL245096B/en active Protection Beyond IP Right Term
- 2016-11-04 JP JP2016216200A patent/JP6370860B2/ja active Active
-
2018
- 2018-02-09 US US15/892,560 patent/US20190030058A1/en not_active Abandoned
- 2018-05-10 HK HK18106100.4A patent/HK1246648B/en unknown
- 2018-07-06 JP JP2018128926A patent/JP6637121B2/ja active Active
- 2018-10-19 HR HRP20181712TT patent/HRP20181712T1/hr unknown
- 2018-11-01 CY CY181101134T patent/CY1120807T1/el unknown
-
2019
- 2019-10-31 HR HRP20191978TT patent/HRP20191978T1/hr unknown
- 2019-12-10 US US16/708,739 patent/US20200376018A1/en not_active Abandoned
- 2019-12-18 JP JP2019227997A patent/JP2020073498A/ja active Pending
- 2019-12-19 CY CY20191101339T patent/CY1122687T1/el unknown
-
2020
- 2020-04-01 NO NO2020008C patent/NO2020008I1/no unknown
-
2021
- 2021-11-05 JP JP2021180965A patent/JP2022025131A/ja active Pending
-
2023
- 2023-10-25 US US18/494,445 patent/US20240238326A1/en not_active Abandoned
- 2023-10-30 JP JP2023185174A patent/JP2024012416A/ja active Pending
-
2025
- 2025-09-29 JP JP2025161821A patent/JP2026004402A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015139553A (ru) | Композиции и способы модуляции smn2 сплайсинга у субъекта | |
| US12049627B2 (en) | Two-tailed self-delivering siRNA | |
| HRP20160261T1 (hr) | Komplementarni antagonisti i njihova uporaba | |
| JP2021513861A (ja) | Ｃａｍｋ２ｄアンチセンスオリゴヌクレオチドおよびその使用 | |
| SI2929031T1 (en) | PCSK9 IRNA assemblies and procedures for their use | |
| JP7291418B2 (ja) | Ｐｃｓｋ９を標的としたアンチセンス核酸 | |
| TW201803989A (zh) | 拮抗ｂ型肝炎病毒之組成物和藥劑及彼等之用途 | |
| JP2012050438A5 (enExample) | ||
| US20180161357A1 (en) | Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als) | |
| US9061068B2 (en) | Polymeric nano-particles for siRNA delivery using charge interaction and covalent bonding | |
| HRP20200117T1 (hr) | Nukleinske kiseline koje se vežu na sdf-1 i njihova upotreba | |
| US20170088839A1 (en) | Dna aptamers for promoting remyelination | |
| JP2017509690A5 (enExample) | ||
| US20250188466A1 (en) | Methods and Compositions for Treatment of Polycystic Kidney Disease | |
| US20190071670A1 (en) | Methods Of Treatment For Alpha-1 Antitrypsin Deficiency | |
| JP2016501528A5 (enExample) | ||
| CN112996913A (zh) | 寡聚核酸分子及其应用 | |
| KR20180080181A (ko) | 다낭포성 신장 질환의 치료 방법 | |
| KR20240101580A (ko) | Hbv 치료를 위한 약학 조합물 | |
| JP2011525531A5 (enExample) | ||
| US20240309383A1 (en) | Small interfering rna targeting hbv and uses thereof | |
| WO2023064809A1 (en) | Oligonucleotides for targeting complement c5 | |
| WO2026061399A1 (en) | Rnai agent for inhibiting expression of xanthine dehydrogenase (xdh) and methods of use thereof | |
| TWI924663B (zh) | 用於抑制ＰＮＰＬＡ３表現之ＲＮＡｉ劑、其醫藥組成物及使用方法 | |
| EP4677090A2 (en) | Compositions and methods for modulating c3 |